Boston – SeromYx Systems is relocating from Cambridge to 299 Washington St., a Cummings Properties science and technology building, in Woburn.
Lab space at Cummings
SeromYx Systems’ 8,000sf Woburn location will house both business and technical operations supporting the development of vaccines, therapies, and diagnostics for the biotech and pharmaceutical industries. Its proprietary Systems Serology platform integrates approaches to antibody profiling, illuminating the effective ones in an effort to inform the creation of more effectual treatments for a wide variety of disease areas. The firm is also actively engaged in projects to help design next generation vaccines and therapeutics for COVID-19.
Cummings Properties business development director Al Diamond worked with Whitehead and Cresa principal Paul Delaney on the transaction. Its in-house architecture, engineering, and construction teams have designed, financed, and erected an entire new 2-story wing at the property to house the facility. Its corner location features a modern façade with a dedicated building entrance, extensive windows, and high ceilings and skylights.
Among SeromYx Systems’ new nearby neighbors are Alloplex Biotherapeutics, Curie Therapeutics, Minovia Therapeutics, Rational Vaccines, Rgenta Therapeutics, SalioGen Therapeutics, and Vaxess Technologies.
